Controversies exist as to what is the best management strategy for vestibular schwannoma (VS). Treatment options include watchful waiting, microsurgery, stereotactic radiosurgery (SRS), and fractionated stereotactic radiotherapy (FSRT). 2 Microsurgery yields local control similar to that accomplished with SRS. 5, 6 Stereotactic radiosurgery represents an excellent treatment option for patients who are not candidates for microsurgery as a result of comorbidities and for those who refuse to undergo surgery. However, in patients with large VSs, especially those with tumor compressing the brainstem, microsurgery is favored over SRS because the latter procedure is unlikely to lead to the immediate relief of mass effect on the brainstem, and because the risk of brainstem injury from SRS is anticipated to be higher as a result of including a larger volume of brainstem in the high-dose zone. Furthermore, there may be a higher risk of hydrocephalus caused by swelling of the large VS after SRS. Clearly, challenges remain when treating large tumors microsurgically. Although nonaudiofacial complications, such as CSF leakage or wound infection, may occur at consistent rates regardless of tumor size, the rates of permanent hearing loss and postoperative facial nerve weakness are greater when larger tumors are resected. 8 In fact, for tumors larger than 4 cm in diameter, published rates of long-term good facial nerve function (House-Brackmann Grade I/II) decrease significantly, approaching 50% or less in the setting of gross-total resection (GTR). 3, 7 In this issue of the Journal of Neurosurgery, van de Langenberg and colleagues 9 report the treatment outcomes of 50 consecutive patients with large VSs (43 with Koos Grade IV lesions) treated with microsurgery aimed at brainstem decompression, followed by planned postoperative SRS. In a second article, 10 they report the outcomes for 33 patients with large VSs measuring 4 cm or less in the maximum dimension, without symptomatic mass effect, and treated with SRS alone. In a study of microsurgery followed by planned SRS, the mean tumor volume reduction after microsurgery was 74.6%.
5 At a median follow-up of 33.8 months, the crude local control rate was 90%, similar to rates reported in other SRS series. 2, 5, 6, 11 The rate of facial nerve function preservation (94%) was also comparable with rates reported in other SRS series.
2,5,6,11 Significantly, van de Langenberg and colleagues note that the preoperative goal in every case was to attain a tumor size amenable to subsequent SRS treatment once brainstem decompression was achieved. At no time were the authors attempting to achieve GTR, and factors, such as tumor consistency, vascularity, or adherence to the adjacent neurovascular structures, did not alter their treatment planning. Although the effort to minimize audiofacial complications is commendable, the authors may be ignoring an important subset of patients in whom GTR can be safely achieved with excellent functional results, that is, younger patients in whom the long-term risk of tumor recurrence following subtotal resection even with SRS is unclear. In such cases, in our opinion, it is still best to begin with a surgical plan consistent with complete resection and to be guided by intraoperative findings that may alter this goal in some circumstances.
In their second study, primary Gamma Knife-based SRS was associated with a local control rate of 88% and with hearing, facial nerve, and trigeminal preservation rates of 58%, 91%, and 86%, respectively.
10 These outcomes were slightly worse than those documented in other SRS series, although these other studies included mostly smaller tumors. 2, 5, 6, 11 Two patients (6%) demonstrated hydrocephalus even in the absence of tumor enlargement.
With regard to the SRS dose parameters for the two studies, it appears that the tumor margin dose, ranging from 9.4 to 11.9 Gy and from 10.3 to 13 Gy in their studies, was slightly lower than the standard margin dose of 12-13 Gy. Furthermore, the authors required only 90% of the VS to be covered by the prescribed dose of 12-13 Gy. This requirement may account for the lower local control rates of 88% to 90%, which are at the low end of the reported local control rates of other SRS series. In the SRS treatment of VS, it is important to respect the tolerance of the brainstem. According to the recent Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) analysis based on SRS data, the brainstem is thought to Editorial This article is one of a series. See Appendix for a complete series listing.
be able to tolerate a maximum brainstem dose of 12.5 Gy, which is the dose required to permanently control VS. 4 With meticulous planning, it is possible to generate a plan with 100% of the tumor receiving the prescribed dose of 12 Gy while keeping the maximum point dose to the brainstem below 12 Gy, further improving the local tumor control rate and keeping the risk of brainstem injury low. In our SRS experience, in which a maximum brainstem point dose of 12 Gy is allowed, we have not observed any significant complications.
One option that has not been considered by the authors is FSRT. In a large study from the University of Heidelberg featuring 106 patients with VS and a median follow-up of 48.5 months, the actuarial local tumor control rates at 3 and 5 years after FSRT were 94.3% and 93%, respectively, and the actuarial useful hearing preservation rate was 94% at 5 years. 1 The rate of radiation-induced toxicity to the trigeminal and facial nerves was 3.4% and 2.3%, respectively. Fractionated stereotactic radiotherapy is certainly a viable treatment option for patients deemed unsuitable for microsurgery or SRS. In general, patients with larger tumors (> 3-4 cm in size) may be better suited for FSRT if microsurgery is not feasible or is refused by patients.
To optimize outcomes, the importance of close collaboration among neurosurgeons, otolaryngologists, and radiation oncologists in the care of patients with VS cannot be overemphasized. It is imperative that patients with VS undergo interdisciplinary evaluation before a final decision is made regarding the best treatment option.
